Letrilliart L, Supper I, Schuers M, Darmon D, Boulet P, Favre M et al (2014) ECOGEN: étude des éléments de la consultation en médecine générale. Exercer 25(114):148–57

Google Scholar 

Santo L, Kang K (2019) National Ambulatory Medical Care Survey: 2019 national summary tables. Natl Center Health Stat 41. Available from: https://doi.org/10.15620/cdc:123251

Assurance Maladie (2023) Médicaments délivrés par les pharmacies de ville par classe ATC - Medic’AM - en cumul annuel 2022 (série labellisée). Available from: https://assurance-maladie.ameli.fr/sites/default/files/2022-medic-am-par-classe-atc_serie-annuelle-labellisee.zip

AFSSAPS (2002) Toplexil 0,33mg/ml, sirop. Agence française de sécurité sanitaire des produits de santé [cited 2023 May 8]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/ct031277.pdf

Haute Autorité de Santé (2011) Toplexil 0,33 mg/ml sans sucre, solution buvable édulcorée à l’acésulfame potassique et Toplexil 0,33 mg/ml, sirop. Haute Autorité de Santé 5. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2012-01/toplexil_14_12_2011_avis_ct11358.pdf

Haute Autorité de Santé (2021) Oxomémazine Cristers 0,33 mg/ml, sirop : mise à disposition d’une nouvelle présentation. Haute Autorité de Santé 4. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-19177_OXOMEMAZINE_CRISTERS_PIS_INS_AvisDef_CT19177.pdf

Haute Autorité de Santé (2008) Toplexil 0,33mg/ml, sirop. Haute Autorité de Santé 2. Available from: https://www.has-sante.fr/upload/docs/application/pdf/ct-5303_toplexil_.pdf

Morice A, Kardos P (2016) Comprehensive evidence-based review on European antitussives. BMJ Open Respir Res 3(1):1–8

Google Scholar 

Rédaction P (2022) Bilan 2023 des médicaments à écarter : pneumologie – ORL. Rev Prescrire 42(470):945–946

Google Scholar 

Rédaction P (2010) Antihistaminiques H1 atropiniques et sédatifs : usages hors AMM. Rev Prescrire 30(324):737

Google Scholar 

Vaillant-Roussel H, Blanchard C, Menini T, Charuel E, Pereira B, Naudet F et al (2023) Projet rebuild the evidence base: une méthode d’interprétation des essais cliniques randomisés et de leur méta-analyse pour présenter aux patients des évaluations solides des bénéfices et des risques. La Revue Exercer 2023(190):81–88

Article  Google Scholar 

Boussageon R, Blanchard C, Charuel E, Menini T, Pereira B, Naudet F et al (2023) Project rebuild the evidence base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients. Therapie 78(4):353–365

Article  PubMed  Google Scholar 

Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev 18(2):e1230

Article  PubMed  PubMed Central  Google Scholar 

Pinho F (2019) Multicentric, randomized, open-label trial to evaluate the superiority of fixed dose combination of oxomemazine, guaifenesin and potassium iodate to guaifenesin monotherapy in acute cough treatment [Internet]. clinicaltrials.gov [cited 2022 Oct 6]. Report No.: NCT01257243. Available from: https://clinicaltrials.gov/ct2/show/NCT01257243

Pinho F (2023) Comparison between oxomemazine, guaifenesin and potassium iodate versus guaifenesin monotherapy in acute cough treatment 7. Available from: https://trialsearch.who.int/Trial2.aspx?TrialID=NCT01257243

Alison M (1965) Therapeutic trials in children and particularly in infants of a new expectorant cough syrup with oxomemazine base. J Med Lyon 46(85):1683–1686

CAS  PubMed  Google Scholar 

Abdelaleem EA, Abdelwahab NS (2018) Green chromatographic method for analysis of some anti-cough drugs and their toxic impurities with comparison to conventional methods. Saudi Pharm J 26(8):1185–1191

Article  PubMed  PubMed Central  Google Scholar 

Albengres E, Guillaume JC, Chevais M (1983) A case-study of recurrent erythema multiforme exudativum with repetitive uses of tetracycline. Ectodermose pluriorificielle répétitive lors de traitements successifs par des tétracyclines. A propos d’un cas. Therapie 38(5):577–9

CAS  PubMed  Google Scholar 

Binder-Foucard F, Reitzer C, Jegu J, Schweitzer B, Koehl F, Kopferschmitt J et al (2012) Use of psychotropic drugs, systemic antihistamines and medications for cough in 6-year-old children: A survey in the Bas-Rhin Region. France Pharmacoepidemiol Drug Saf 21(10):1112–1117

Article  PubMed  Google Scholar 

Pujet JC, Keddad K, Sévenier F, Jolivet-Landreau I (2002) Comparative study of two antitussive drugs in the treatment of acute dry cough of infectious origin (prospective, randomized, single blind study). Therapie 57(5):457–463

CAS  PubMed  Google Scholar 

von Deschwanden B, von Deschwanden P (1967) Experiences with the new cough regulator Toplexil. Praxis 56(36):1221–1223

Google Scholar 

Chapuis, Dalmais, Belpois, Meunier (1965) [Oxomemazine (new antihistaminic). Its value in general medicine]. Lyon Med 214(38):413–6

Church MK, Maurer M, Simons FER, Bindslev-Jensen C, van Cauwenberge P, Bousquet J et al (2010) Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 65(4):459–466

Article  CAS  PubMed  Google Scholar 

Smith SM, Schroeder K, Fahey T (2014) Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database Syst Rev 2014(11):CD001831